Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(1):6-8; doi:10.1093/jnci/92.1.6
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 1, 6-8, January 5, 2000
© 2000 Oxford University Press

NEWS

Leukemia Drug Heralds Molecularly Targeted Era

Brian Vastag

When Brian Druker was a medical student, he envisioned destroying cancer without devastating the patient. "My most vivid memory was when we learned about chemotherapy. I thought, ‘My God, this stuff works but it's horrible.' "



View larger version (110K):
[in this window]
[in a new window]
  		Dr. Brian Drucker

 
Nearly 20 years later, Druker the physician has helped a better way materialize in the form of STI-571, a drug that selectively targets chronic myelogenous leukemia cells without any of the traditional chemotherapy side effects. The darling of two recent scientific conferences, STI-571, which is owned by Novartis Pharmaceuticals Corp., East Hanover, N.J., passed phase I clinical testing with promising results and has entered phase II trials that will enroll several hundred patients in the United States and Europe.

If the drug continues to prove its worth against CML, which strikes 4,500 Americans annually, it will hit the market as one of the first representatives of a broad group of drugs . . . [Full Text of this Article]

A String of Firsts

Homing In

A Prototype Drug


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. M. Collins
Innovations in Phase 1 Trial Design: Where Do We Go Next?
Clin. Cancer Res., October 1, 2000; 6(10): 3801 - 3802.
[Full Text]